Zimberelimab (Yu Duo)
Revision as of 02:13, 11 August 2023 by Jwarner (talk | contribs) (Jwarner moved page Zimberelimab (AB-122) to Zimberelimab (Yu Duo): brand name)
Mechanism of action
PD-1 inhibitor
Diseases for which it is used
History of changes in NMPA indication
- 2021-08-30: Approved for the treatment of recurrent or refractory classical Hodgkin’s lymphoma (cHL).
Also known as
- Code names: AB-122, GLS-010, WBP-3055
- Generic name: sepalizumab
- Brand name: Yu Duo